INNOVATIVE FEDERAL STRATEGIES, LLC for ACURX PHARMACEUTICALS, INC.
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Defense DEF
H.R.3838/S.2296, National Defense Authorization Act, 2026, Title II, all provisions related to biodefense preparedness.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ERYNN D HOOK | — |
| CARL KIME | — |
| LETITIA WHITE | — |
Budget/Appropriations BUD
H.R.4026/S.2572, Department of Defense Appropriations Bill, 2026, Title IV, all provisions related to biodefense preparedness. H.R.5304/S.2587, Departments of Labor, Health and Human Services, Education, and Related Agencies Appropriations bill, Title II, all provisions related research and clinical trials for the development of antibiotics for infections caused by bacteria listed as priority pathogens.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ERYNN D HOOK | — |
| CARL KIME | — |
| LETITIA WHITE | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.